<p>Abivax（納斯達克股票代碼：ABVX - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的研究分析師從 “賣出” 評級上調至 “持有” 評級。</p>
<p>其他幾家研究公司也最近對 ABVX 發表了評論。花旗集團在 1 月 8 日（星期四）發佈的研究報告中重申了對 Abivax 股票的 “市場跑贏大盤” 評級。摩根士丹利在 1 月 9 日（星期五）的研究報告中將 Abivax 的目標價格從 101.00 美元上調至 145.00 美元，並給予該股票 “增持” 評級。Oppenheimer 在 1 月 8 日（星期四）的報告中設定了 Abivax 的目標價格為 131.00 美元。傑富瑞金融集團在 3 月 16 日（星期一）開始對 Abivax 股票進行覆蓋，設定了 “買入” 評級和 160.00 美元的價格目標。最後，Weiss Ratings 在 1 月 21 日（星期三）的報告中重申了對 Abivax 股票的 “賣出（d-）” 評級。一位分析師給予該股票 “強烈買入” 評級，十三位分析師給予 “買入” 評級，一位分析師對該公司的股票給予 “賣出” 評級。根據 MarketBeat.com 的數據，Abivax 的共識評級為 “適度買入”，平均目標價格為 137.15 美元。</p>
<p><strong>查看我們最新的 Abivax 股票報告</strong></p>
<h2>Abivax 股票下跌 1.9%</h2>
<p>納斯達克：ABVX 的股票在週五以 120.16 美元開盤。該公司的 50 日移動平均價格為 119.10 美元，200 日移動平均價格為 114.65 美元。該公司的市值為 95.3 億美元，市盈率為-22.38，貝塔值為 1.68。Abivax 的 52 周最低價為 5.59 美元，52 周最高價為 148.83 美元。</p>
<p>Abivax（納斯達克：ABVX - 獲取免費報告）最後一次公佈季度財報是在 2 月 14 日（星期六）。該公司報告本季度每股收益為（1.20 美元）。該業務本季度的收入為 52 萬美元。作為一個整體，股票分析師預計 Abivax 在當前年度將發佈-2.83 的每股收益。</p>
<h2>對 Abivax 的對沖基金看法</h2>
<p>幾家對沖基金最近修改了對 ABVX 的持股。WPG Advisers LLC 在第四季度將其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 現在擁有 454 股該公司的股票，價值 61,000 美元，在此期間又購買了 253 股。凱通國際資產管理有限公司在第四季度將其在 Abivax 的持股增加了 661.5%。凱通國際資產管理有限公司現在擁有 396 股該公司的股票，價值 53,000 美元，在此期間又收購了 344 股。EverSource Wealth Advisors LLC 在第三季度將其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 現在擁有 377 股該公司的股票，價值 32,000 美元，在此期間又收購了 369 股。First Horizon Corp 在第三季度購買了 Abivax 的新股份，價值約 36,000 美元。最後，夏威夷銀行在第四季度將其在 Abivax 的持股增加了 14.9%。夏威夷銀行現在擁有 3,454 股該公司的股票，價值 466,000 美元，在上個季度又收購了 448 股。目前 47.91% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Abivax</h2>
<p>（獲取免費報告）</p>
<p>Abivax 成立於 2013 年，總部位於法國巴黎，是一家臨牀階段的生物製藥公司，專注於發現和開發針對慢性炎症性疾病和病毒感染的新療法。該公司的技術平台針對宿主 RNA 生物發生，以調節關鍵免疫通路，提供一種旨在疾病修飾和改善安全性特徵的差異化方法。</p>
<p>Abivax 的主要臨牀資產 obefazimod（ABX464）正在評估用於潰瘍性結腸炎和其他炎症性疾病。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Abivax 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Abivax 嗎？</h2>
<p>在你考慮 Abivax 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Abivax 並不在名單上。</p>
<p>雖然 Abivax 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ABVX

<p>華爾街禪將 Abivax (NASDAQ:ABVX) 的評級從 “賣出” 上調至 “持有”。其他公司如花旗集團和摩根士丹利也給予了積極的評級，其中摩根士丹利將目標價上調至 145 美元。Abivax 的股票目前下跌 1.9%，交易價格為 120.16 美元，市值為 95.3 億美元。該公司報告的季度每股收益為（1.20 美元），預計本年度每股收益為-2.83 美元。機構投資者持有該股票的 47.91%</p>

<p>Abivax (NASDAQ:ABVX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Abivax（納斯達克股票代碼：ABVX - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的研究分析師從 “賣出” 評級上調至 “持有” 評級。</p>
</div><p>Several other research firms have also recently commented on ABVX. Citigroup restated a &#34;market outperform&#34; rating on shares of Abivax in a research report on Thursday, January 8th. Morgan Stanley boosted their price target on Abivax from $101.00 to $145.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, January 9th. Oppenheimer set a $131.00 price target on Abivax in a report on Thursday, January 8th. Jefferies Financial Group started coverage on shares of Abivax in a research note on Monday, March 16th. They set a &#34;buy&#34; rating and a $160.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Abivax in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Abivax has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $137.15.</p>
<div class="lb-trans"><p>其他幾家研究公司也最近對 ABVX 發表了評論。花旗集團在 1 月 8 日（星期四）發佈的研究報告中重申了對 Abivax 股票的 “市場跑贏大盤” 評級。摩根士丹利在 1 月 9 日（星期五）的研究報告中將 Abivax 的目標價格從 101.00 美元上調至 145.00 美元，並給予該股票 “增持” 評級。Oppenheimer 在 1 月 8 日（星期四）的報告中設定了 Abivax 的目標價格為 131.00 美元。傑富瑞金融集團在 3 月 16 日（星期一）開始對 Abivax 股票進行覆蓋，設定了 “買入” 評級和 160.00 美元的價格目標。最後，Weiss Ratings 在 1 月 21 日（星期三）的報告中重申了對 Abivax 股票的 “賣出（d-）” 評級。一位分析師給予該股票 “強烈買入” 評級，十三位分析師給予 “買入” 評級，一位分析師對該公司的股票給予 “賣出” 評級。根據 MarketBeat.com 的數據，Abivax 的共識評級為 “適度買入”，平均目標價格為 137.15 美元。</p>
</div><p><strong>View Our Latest Stock Report on Abivax</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Abivax 股票報告</strong></p>
</div><h2>Abivax Stock Down 1.9%</h2>
<div class="lb-trans"><h2>Abivax 股票下跌 1.9%</h2>
</div><p>Shares of NASDAQ:ABVX opened at $120.16 on Friday. The company's 50-day moving average price is $119.10 and its 200 day moving average price is $114.65. The company has a market cap of $9.53 billion, a PE ratio of -22.38 and a beta of 1.68. Abivax has a fifty-two week low of $5.59 and a fifty-two week high of $148.83.</p>
<div class="lb-trans"><p>納斯達克：ABVX 的股票在週五以 120.16 美元開盤。該公司的 50 日移動平均價格為 119.10 美元，200 日移動平均價格為 114.65 美元。該公司的市值為 95.3 億美元，市盈率為-22.38，貝塔值為 1.68。Abivax 的 52 周最低價為 5.59 美元，52 周最高價為 148.83 美元。</p>
</div><p>Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The business had revenue of $0.52 million for the quarter. As a group, equities analysts anticipate that Abivax will post -2.83 EPS for the current year.</p>
<div class="lb-trans"><p>Abivax（納斯達克：ABVX - 獲取免費報告）最後一次公佈季度財報是在 2 月 14 日（星期六）。該公司報告本季度每股收益為（1.20 美元）。該業務本季度的收入為 52 萬美元。作為一個整體，股票分析師預計 Abivax 在當前年度將發佈-2.83 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Abivax</h2>
<div class="lb-trans"><h2>對 Abivax 的對沖基金看法</h2>
</div><p>Several hedge funds have recently modified their holdings of ABVX. WPG Advisers LLC lifted its holdings in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after buying an additional 253 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company's stock worth $53,000 after acquiring an additional 344 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock worth $32,000 after acquiring an additional 369 shares during the period. First Horizon Corp bought a new stake in Abivax in the third quarter worth about $36,000. Finally, Bank of Hawaii raised its position in Abivax by 14.9% in the fourth quarter. Bank of Hawaii now owns 3,454 shares of the company's stock worth $466,000 after acquiring an additional 448 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金最近修改了對 ABVX 的持股。WPG Advisers LLC 在第四季度將其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 現在擁有 454 股該公司的股票，價值 61,000 美元，在此期間又購買了 253 股。凱通國際資產管理有限公司在第四季度將其在 Abivax 的持股增加了 661.5%。凱通國際資產管理有限公司現在擁有 396 股該公司的股票，價值 53,000 美元，在此期間又收購了 344 股。EverSource Wealth Advisors LLC 在第三季度將其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 現在擁有 377 股該公司的股票，價值 32,000 美元，在此期間又收購了 369 股。First Horizon Corp 在第三季度購買了 Abivax 的新股份，價值約 36,000 美元。最後，夏威夷銀行在第四季度將其在 Abivax 的持股增加了 14.9%。夏威夷銀行現在擁有 3,454 股該公司的股票，價值 466,000 美元，在上個季度又收購了 448 股。目前 47.91% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Abivax</h2>
<div class="lb-trans"><h2>關於 Abivax</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.</p>
<div class="lb-trans"><p>Abivax 成立於 2013 年，總部位於法國巴黎，是一家臨牀階段的生物製藥公司，專注於發現和開發針對慢性炎症性疾病和病毒感染的新療法。該公司的技術平台針對宿主 RNA 生物發生，以調節關鍵免疫通路，提供一種旨在疾病修飾和改善安全性特徵的差異化方法。</p>
</div><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p>
<div class="lb-trans"><p>Abivax 的主要臨牀資產 obefazimod（ABX464）正在評估用於潰瘍性結腸炎和其他炎症性疾病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Abivax</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Abivax 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ABVX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abivax Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Abivax 嗎？</h2>
</div><p>Before you consider Abivax, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Abivax 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Abivax 並不在名單上。</p>
</div><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Abivax 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Abivax (NASDAQ:ABVX) Upgraded to "Hold" at Wall Street Zen

Market Beat

Abivax SA

花旗

摩根士丹利

奧本海默控股

Jefferies Financial

第一地平線

夏威夷銀行

CITIGROUP INC 6.250 NON CUM SER II PFD WI

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

BANK OF HAWAII CORPORATION DEP SHS REPSTG 1/40TH INT SH NON CUM PER

BANK OF HAWAII CORP 4.375% DEP SHS REPSTG 1/40TH PFD SER A

Abivax（NASDAQ 代碼：ABVX）在 Wall Street Zen 被上調至 “持有” 評級